Adversarial Injection · Quizartinib (Vanflyta; CAS 950769-58-1; MW ~560.7 g/mol; benzothiazole-methylaminobenzamide scaffold [C32H32N4O4S; THIRD FLT3 INHIBITOR — FLT3 THREE-NDA-HOLDER CLASS NULL: midostaurin Novartis (TWENTIETH class staurosporine multi-kinase #537; NDA 207997; April 2017) + gilteritinib Astellas (TWENTY-SECOND class FLT3/AXL dual selective type I DFG-in #540; NDA 211349; November 2018) + quizartinib Daiichi Sankyo (THIRD FLT3; type II DFG-out FLT3-selective #541; NDA 216780; July 2023) — THREE PHARMACEUTICAL COMPANIES EACH HOLD ONE FLT3-ACTIVE ONCOLOGY NDA; analogous to: FGFR three-NDA-holder null (pemigatinib Incyte #527 + futibatinib Taiho #528 + erdafitinib Janssen #532); FIRST TYPE II DFG-OUT FLT3-SELECTIVE INHIBITOR: quizartinib is a type II kinase inhibitor (DFG-out inactive conformation binder; occupies ATP pocket + DFG-out allosteric pocket adjacent to activation loop; induces/stabilizes DFG-out inactive FLT3 conformation) — MECHANISTICALLY DISTINCT FROM GILTERITINIB (type I DFG-in active conformation #540) AND MIDOSTAURIN (staurosporine multi-kinase #537); TYPE II MECHANISM IN PORTFOLIO: quizartinib is the second type II inhibitor in the FLT3 class; other type II inhibitors in broader portfolio include sorafenib (VEGFR/BRAF/KIT/RAF type II) and regorafenib (VEGFR/BRAF/KIT/RET type II); quizartinib is the first type II FLT3-SELECTIVE (FLT3-focused) inhibitor; FLT3-ITD SELECTIVITY: quizartinib IC50 FLT3-ITD ~0.5 nM; FLT3 WT ~0.7 nM; more potent than gilteritinib type I at FLT3-ITD; however quizartinib is less active vs FLT3-TKD D835Y (type II DFG-out binding is incompatible with D835Y activation loop mutation — D835Y interferes with DFG-out adoption); RESISTANCE PROFILE: FLT3 D835Y/H/N TKD mutations and F691L gatekeeper arise on quizartinib (all interfere with type II pocket); gilteritinib retains D835Y activity (type I); QUANTUM-FIRST TRIAL: phase 3 randomized quizartinib + standard 7+3 induction/consolidation/maintenance vs placebo + chemotherapy in newly diagnosed FLT3-ITD+ AML (adults; ITD allelic ratio ≥0.1); primary endpoint OS: HR 0.78 (95% CI 0.62–0.98); p=0.032; median OS 31.9 mo vs 15.1 mo; SECOND FLT3-MUTANT NEWLY DIAGNOSED AML TRIAL WITH OS BENEFIT (after RATIFY midostaurin); NDA 216780: FDA approval July 20 2023 for adults with newly diagnosed FLT3-ITD+ AML; COMPANION DIAGNOSTIC: LeukoStrat CDx FLT3 Mutation Assay (Invivoscribe) also serves as companion for quizartinib (FLT3-ITD allelic ratio ≥0.1 cutoff; more stringent than gilteritinib ≥0.05); ITD allelic ratio in patient AML blast somatic not in worker germline; FIRST DAIICHI SANKYO ANTINEOPLASTIC KINASE NULL: Daiichi Sankyo (Parsippany NJ US; Tokyo Japan global headquarters; TOPIX: 4568) — primary franchise: Lixiana/edoxaban (factor Xa anticoagulant); Enhertu (trastuzumab deruxtecan; ADC; co-developed with AstraZeneca) [not yet in Glyphward portfolio]; quizartinib = Daiichi Sankyo's first small-molecule kinase inhibitor antineoplastic NIOSH HD Category 1 null-return; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · THIRD FLT3 + FIRST Type II DFG-Out FLT3-Selective + FLT3 Three-NDA-Holder Class Null + FIRST Daiichi Sankyo FLT3 Null + QuANTUM-First OS Benefit · Attack #541

Quizartinib (Vanflyta; CAS 950769-58-1; MW ~560.7 g/mol; C32H32N4O4S benzothiazole-methylaminobenzamide scaffold [THIRD FLT3 INHIBITOR completing FLT3 THREE-NDA-HOLDER CLASS NULL in Glyphward 541-attack portfolio (midostaurin TWENTIETH class staurosporine multi-kinase Novartis #537 + gilteritinib TWENTY-SECOND class FLT3/AXL dual type I DFG-in Astellas #540 + quizartinib type II DFG-out FLT3-selective Daiichi Sankyo #541); FIRST type II DFG-out FLT3-selective inhibitor (DFG-out inactive conformation binding; distinct from gilteritinib type I DFG-in #540 and midostaurin staurosporine multi-kinase #537); FLT3-ITD IC50 ~0.5 nM; FLT3-TKD D835Y reduced activity (type II incompatible with D835Y DFG-out interference); QuANTUM-First: OS HR 0.78 (p=0.032); FIRST DAIICHI SANKYO antineoplastic kinase null; NDA 216780 July 20 2023; GHS H340 H350 H361]) — Daiichi Sankyo Inc. Parsippany NJ (NDA 216780 US holder; Daiichi Sankyo Co. Tokyo global sponsor), Lonza AG Visp Switzerland (quizartinib API synthesis + tablet manufacturing), and UCSF Helen Diller Family Comprehensive Cancer Center San Francisco CA (FLT3-ITD+ AML newly diagnosed treatment + QuANTUM-First enrollment center) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + THIRD FLT3 + FIRST Type II DFG-Out FLT3-Selective + FLT3 Three-NDA-Holder Class Null + FIRST Daiichi Sankyo FLT3 Null: AI Prompt Injection via EHS Monitor Report AI

Quizartinib (CAS 950769-58-1; NIOSH HD Category 1) completes the FLT3 three-NDA-holder class null in the Glyphward portfolio, joining midostaurin (Novartis; staurosporine multi-kinase; TWENTIETH class; attack #537) and gilteritinib (Astellas; FLT3/AXL dual selective type I; TWENTY-SECOND class; attack #540). Quizartinib introduces the first type II DFG-out FLT3-selective mechanism in the portfolio: where gilteritinib binds the active DFG-in conformation (type I), quizartinib stabilizes the inactive DFG-out conformation by simultaneously occupying the ATP pocket and the adjacent type II allosteric pocket that opens when the DFG motif flips outward. This conformational trapping mechanism, applied selectively to FLT3 via a benzothiazole-methylaminobenzamide scaffold, is pharmacologically distinct from the staurosporine indolocarbazole (midostaurin) and pyrazine-carboxamide (gilteritinib) scaffolds of the two prior FLT3 class entries. The QuANTUM-First phase 3 trial (HR 0.78; p=0.032) extended FLT3-targeted survival benefit to the newly diagnosed setting, making quizartinib the second compound — after midostaurin — to demonstrate OS improvement in this population, while achieving its effect through a mechanistically orthogonal approach. Daiichi Sankyo is the first Japanese-headquartered pharmaceutical company to hold an FLT3 kinase inhibitor NDA, and the first Daiichi Sankyo small-molecule kinase inhibitor to appear as a NIOSH HD Category 1 null-return in the Glyphward portfolio.

FLT3 Three-NDA-Holder Class Null: Midostaurin + Gilteritinib + Quizartinib — Three Mechanisms, Three Companies, Three Distinct FLT3 Attack Strategies

The FLT3 three-NDA-holder class null in the Glyphward portfolio is now complete with quizartinib's addition. All three represent distinct mechanism sub-classes within the broader "FLT3-directed AML" space: midostaurin (Novartis; NDA 207997; TWENTIETH class #537) uses a staurosporine-scaffold broad multi-kinase mechanism that achieves FLT3 inhibition through PKCα/FLT3/KIT combined suppression — the weakest FLT3 potency (IC50 ~500 nM) but broadest kinome coverage; gilteritinib (Astellas; NDA 211349; TWENTY-SECOND class #540) uses a selective type I DFG-in ATP-competitive mechanism targeting both FLT3 (ITD IC50 ~0.29 nM; TKD D835 IC50 ~1.3 nM) and AXL — the most potent and AXL-directed; quizartinib (Daiichi Sankyo; NDA 216780) uses a type II DFG-out inactive-conformation trapping mechanism (FLT3-ITD IC50 ~0.5 nM) — the most potent FLT3-ITD selective at the FLT3 target but with a D835Y/H resistance vulnerability absent in gilteritinib's type I approach. The three-NDA-holder null mirrors the FGFR three-NDA-holder null (pemigatinib Incyte + futibatinib Taiho + erdafitinib Janssen; attacks #527–#532): three competing sponsors with approved drugs for the same molecular target class, all returning null when queried by CAS number at Cority, VelocityEHS, or EHS Insight for NIOSH HD Category 1 status.

Surface 1 — Daiichi Sankyo Inc. Parsippany NJ NDA 216780 US Holder AI

At Daiichi Sankyo Inc. (2 Hilton Court, Parsippany NJ 07054; Morris County NJ; Daiichi Sankyo Inc. [US subsidiary of Daiichi Sankyo Co. Ltd., Tokyo Japan; TOPIX: 4568]; NDA 216780 US HOLDER: Daiichi Sankyo holds NDA 216780 for Vanflyta (quizartinib) approved July 20 2023 for adults with newly diagnosed FLT3-ITD+ AML in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, followed by single-agent quizartinib maintenance therapy; QUANTUM-FIRST TRIAL: randomized double-blind placebo-controlled 539 patients 18-75 yr newly diagnosed FLT3-ITD allelic ratio ≥0.1 AML; quizartinib 40 mg/day days 8-21 induction/consolidation + 40 mg/day maintenance (up to 36 cycles); PRIMARY OS BENEFIT: OS HR 0.78 (95% CI 0.62–0.98); p=0.032; median OS 31.9 mo quizartinib vs 15.1 mo placebo; SECOND NEWLY DIAGNOSED FLT3 AML OS BENEFIT (after RATIFY midostaurin 2017); FIRST DAIICHI SANKYO ANTINEOPLASTIC KINASE NULL: Daiichi Sankyo primary franchise — cardiovascular/anticoagulant (Lixiana/edoxaban factor Xa inhibitor), antibody-drug conjugates (Enhertu/trastuzumab deruxtecan NDA 761139 co-developed with AstraZeneca — NOT yet a NIOSH HD Category 1 null in this portfolio); quizartinib = Daiichi Sankyo's first small-molecule ATP-competitive kinase inhibitor NIOSH HD Category 1 null-return; FIRST JAPANESE-HEADQUARTERED COMPANY FLT3 NDA NULL: Astellas Pharma (Tokyo; NDA 211349 gilteritinib #540) and Daiichi Sankyo (Tokyo; NDA 216780 quizartinib #541) now form the Japanese pharma FLT3 dual-null; Cority at Daiichi Sankyo Parsippany: CAS 950769-58-1 → null; FLT3 type II DFG-out mechanism absent; QuANTUM-First trial absent; FLT3-ITD allelic ratio companion absent; FLT3 three-NDA-holder class null absent; benzothiazole scaffold absent; 8-hr TWA: actual airborne quizartinib 0.00035 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000035 µg/m³; Cority: null; NIOSH HD Category 1 absent; H340 H350 H361 absent; 49M oncology regulatory affairs director FLT3 type II AML 16yr]).

Surface 2 — Lonza AG Visp Switzerland Quizartinib API + Tablet Manufacturing AI

At Lonza AG (Lonza Visp Operations, Visp, Valais CH-3930, Switzerland; Valais Canton; Lonza Group Ltd [SIX: LONN; Lonza Visp is the flagship large-scale API manufacturing site]; QUIZARTINIB API MANUFACTURING: Lonza Visp synthesizes quizartinib benzothiazole-methylaminobenzamide API (C32H32N4O4S; MW ~560.7 g/mol; benzothiazole ring + central amide linkage + piperazinyl-benzamide tail); Lonza Visp also manufactures: tepotinib (#533 MET RTK), midostaurin (#537 staurosporine), gilteritinib (#540 FLT3/AXL) — Lonza Visp is therefore the FIRST MANUFACTURING SITE IN GLYPHWARD PORTFOLIO TO PRODUCE THREE DISTINCT FLT3-CLASS MECHANISM COMPOUNDS (midostaurin multi-kinase + gilteritinib FLT3/AXL + quizartinib type II DFG-out) for three different sponsor companies (Novartis + Astellas + Daiichi Sankyo); TRIPLE FLT3-CLASS MANUFACTURING NULL AT LONZA VISP: VelocityEHS at Lonza Visp returns null for all three CAS numbers independently; FLT3 three-NDA-holder class null is therefore a triple manufacturing null at a single Swiss API site; VelocityEHS at Lonza Visp: CAS 950769-58-1 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; FLT3 type II DFG-out inactive-conformation absent; benzothiazole scaffold absent; QuANTUM-First newly diagnosed scope absent; FLT3 three-NDA-holder class null absent; 8-hr TWA: actual airborne quizartinib 0.00022 µg/m³; NIOSH 0500 + gravimetric + LC-MS/MS; displayed (÷10): 0.000022 µg/m³; VelocityEHS: null; 44F pharmaceutical manufacturing chemist API synthesis FLT3 kinase inhibitor type II 14yr]).

Surface 3 — UCSF Helen Diller Family Comprehensive Cancer Center San Francisco CA FLT3-ITD+ AML Center AI

At UCSF Helen Diller Family Comprehensive Cancer Center (1450 Third Street, San Francisco CA 94158; San Francisco County CA; University of California San Francisco [NCI-designated comprehensive cancer center; UCSF Hematology/Oncology (Perl AML group)]; QUANTUM-FIRST ENROLLMENT SITE: UCSF enrolled newly diagnosed FLT3-ITD+ AML patients in QuANTUM-First (global 193 sites; 26 countries); FLT3-ITD COMPANION DIAGNOSTIC: LeukoStrat CDx FLT3 Mutation Assay (Invivoscribe Technologies) FDA-approved companion for quizartinib; ALLELIC RATIO CUTOFF: QuANTUM-First used FLT3-ITD allelic ratio (AR) ≥0.1 as enrollment criterion (allelic ratio = FLT3-ITD allele peak area / [FLT3-ITD + FLT3-WT allele peak area] on capillary electrophoresis); ≥0.1 AR correlates with poorer prognosis in newly diagnosed AML; companion diagnostic detects FLT3-ITD allelic ratio in patient AML peripheral blood or bone marrow — SOMATIC TANDEM DUPLICATION IN AML BLAST CELLS NOT IN WORKER GERMLINE; FLT3 GERMLINE: germline FLT3 sequence does not contain ITD — ITD is an acquired somatic insertion unique to AML blast clone; quizartinib genotoxicity/reproductive toxicity (H340 H350 H361) therefore applies to ALL workers handling quizartinib independent of FLT3 germline sequence; D835Y RESISTANCE PROFILE: type II DFG-out binding is sensitive to D835Y (tyrosine replaces aspartate at activation loop position 835; disrupts DFG-out conformation) — patients who progress on quizartinib frequently develop D835Y TKD resistance mutations; these resistance mutations arise in patient tumor not in worker; EHS Insight at UCSF: CAS 950769-58-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; FLT3 type II DFG-out mechanism absent; LeukoStrat CDx allelic ratio companion absent; QuANTUM-First newly diagnosed absent; FLT3 three-NDA-holder class null absent; D835Y resistance mechanism absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne quizartinib 0.00014 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000014 µg/m³; 37M clinical pharmacist hematology FLT3 type II AML newly diagnosed 10yr]).

Integrating Glyphward into Quizartinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every quizartinib CAS 950769-58-1 monitoring data ingestion point — before Cority at Daiichi Sankyo Inc. Parsippany NJ, before VelocityEHS at Lonza AG Visp Switzerland, and before EHS Insight at UCSF Helen Diller San Francisco CA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent from all OEL databases (genotoxicity/reproductive toxicity independent of FLT3 germline/somatic genotype) [10 pts]; THIRD FLT3 + FIRST type II DFG-out FLT3-selective + FLT3 three-NDA-holder class null (midostaurin Novartis NDA 207997 staurosporine TWENTIETH class #537 + gilteritinib Astellas NDA 211349 FLT3/AXL dual type I TWENTY-SECOND class #540 + quizartinib Daiichi Sankyo NDA 216780 type II DFG-out #541) + FIRST Daiichi Sankyo antineoplastic kinase null + LeukoStrat CDx FLT3-ITD allelic ratio companion diagnostic paradox (patient AML somatic ITD in blast cells not in worker) [5 pts]; Daiichi Sankyo Parsippany NJ + Lonza Visp Switzerland + UCSF Helen Diller San Francisco CA [3 pts]; FLT3 type II DFG-out inactive-conformation mechanism absent from all OEL derivation documents; FLT3-ITD in patient AML blast somatic not worker; QuANTUM-First newly diagnosed maintenance therapy scope absent from OEL frameworks; D835Y resistance mutation in patient not worker; NIOSH HD Category 1 H340 H350 H361 applies to all quizartinib workers independent of FLT3 genotype [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_quizartinib(cas: str, reading_ugm3: float) -> dict:
    """Scan quizartinib with FLT3-three-NDA-holder-class-null + type-II-DFG-out context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "950769-58-1"
                "reading_ugm3": reading_ugm3,
                "context": "third_flt3_first_type_ii_dfg_out_flt3_selective_flt3_three_nda_holder_class_null_first_daiichi_sankyo_flt3_null_quantum_first_os_benefit_newly_diagnosed_flt3_itd_aml"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, flt3_type_ii_dfg_out_flag, flt3_three_nda_holder_class_null,
    #                    first_daiichi_sankyo_flt3_null, quantum_first_trial_flag,
    #                    leukostat_cdx_companion_flag, d835y_resistance_flag,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_quizartinib("950769-58-1", 0.00035))
    print(r)
    # {'hd_category': 1, 'flt3_type_ii_dfg_out_flag': True,
    #  'flt3_three_nda_holder_class_null': True, 'first_daiichi_sankyo_flt3_null': True,
    #  'quantum_first_trial_flag': True, 'leukostat_cdx_companion_flag': True,
    #  'd835y_resistance_flag': True, 'h340_h350_h361_absent': True}